Published in Diabetes on January 20, 2015
Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends Pharmacol Sci (2017) 0.77
The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities. BMB Rep (2016) 0.76
Endothelial Estrogen Receptor-α Does Not Protect Against Vascular Stiffness Induced by Western Diet in Female Mice. Endocrinology (2016) 0.76
Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent. Diabetol Metab Syndr (2015) 0.75
High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. Nutrients (2017) 0.75
Application of an In Vivo Hepatic Triacylglycerol Production Method in the Setting of a High-Fat Diet in Mice. Nutrients (2016) 0.75
Linagliptin alleviates fatty liver disease in diabetic db/db mice. World J Diabetes (2016) 0.75
Peroxisome Proliferator-Activated Receptor-α Accelerates α-Chlorofatty Acid Catabolism. J Lipid Res (2016) 0.75
Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol (2017) 0.75
Gestational exercise protects adult male offspring from high-fat diet-induced hepatic steatosis. J Hepatol (2015) 0.75
Uric Acid for Cardiovascular Risk: Dr. Jekyll or Mr. Hide? Diseases (2016) 0.75
Prevalence and trends in obesity among US adults, 1999-2008. JAMA (2010) 50.58
Mechanisms for insulin resistance: common threads and missing links. Cell (2012) 6.85
Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med (1999) 5.65
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology (2010) 5.35
Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature (2007) 4.54
Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem (2005) 4.30
SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab (2012) 3.69
Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes (2006) 3.69
The role of gut hormones in glucose homeostasis. J Clin Invest (2007) 3.36
Quantitative analysis and molecular species fingerprinting of triacylglyceride molecular species directly from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry. Anal Biochem (2001) 3.09
Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab (2011) 2.75
Unsaturated fatty acids inhibit transcription of the sterol regulatory element-binding protein-1c (SREBP-1c) gene by antagonizing ligand-dependent activation of the LXR. Proc Natl Acad Sci U S A (2001) 2.65
Determining hepatic triglyceride production in mice: comparison of poloxamer 407 with Triton WR-1339. J Lipid Res (2005) 2.61
The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr Rev (2010) 2.59
Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A (2011) 2.39
Glucose metabolism in vivo in four commonly used inbred mouse strains. Diabetes (2008) 2.38
Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem (2009) 2.28
Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol (2010) 2.09
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology (2006) 2.08
Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes (2013) 2.03
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology (2010) 1.86
Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem (2012) 1.67
The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab (2012) 1.66
Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab (2012) 1.64
High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology (2013) 1.56
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol (2013) 1.56
Dietary fructose in nonalcoholic fatty liver disease. Hepatology (2013) 1.39
Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes (2011) 1.37
The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med (2011) 1.35
Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology (2012) 1.27
Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One (2012) 1.18
Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One (2010) 1.08
Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS One (2011) 1.08
Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol (2013) 1.04
Effect of diet on expression of genes involved in lipid metabolism, oxidative stress, and inflammation in mouse liver-insights into mechanisms of hepatic steatosis. PLoS One (2014) 1.04
Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol (2007) 1.02
Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One (2012) 1.01
Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism. Mol Med Rep (2011) 1.00
Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology (2012) 0.99
Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity. Metabolism (2014) 0.98
Potential of incretin-based therapies for non-alcoholic fatty liver disease. J Diabetes Complications (2013) 0.97
GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One (2012) 0.95
Effects of insulin resistance and hepatic lipid accumulation on hepatic mRNA expression levels of apoB, MTP and L-FABP in non-alcoholic fatty liver disease. Exp Ther Med (2011) 0.94
Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci (2013) 0.94
Acyl chain dependence of diacylglycerol activation of protein kinase C activity in vitro. Biochem Biophys Res Commun (1996) 0.94
Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology (2014) 0.93
Fructose and risk of cardiometabolic disease. Curr Atheroscler Rep (2012) 0.92
Elevated glucose represses liver glucokinase and induces its regulatory protein to safeguard hepatic phosphate homeostasis. Diabetes (2011) 0.91
Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis Tissue Repair (2013) 0.88
Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect. Hepatology (2013) 0.86
Impact of various exercise modalities on hepatic mitochondrial function. Med Sci Sports Exerc (2014) 0.85
The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis (2013) 0.84
The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep (2013) 0.84
The DPP-4 inhibitor MK0626 and exercise protect islet function in early pre-diabetic kkay mice. Peptides (2013) 0.81
Liquid fructose downregulates Sirt1 expression and activity and impairs the oxidation of fatty acids in rat and human liver cells. Biochim Biophys Acta (2014) 0.79
Direct effects of fructose metabolism on fatty acid oxidation in a recombined rat liver mitochondria-hish speed supernatant system. Biochim Biophys Acta (1976) 0.78